{"id":536230,"date":"2021-09-09T08:03:51","date_gmt":"2021-09-09T12:03:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\/"},"modified":"2021-09-09T08:03:51","modified_gmt":"2021-09-09T12:03:51","slug":"krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\/","title":{"rendered":"Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:left\">\n          <em>Data include evaluation of investigational B-VEC in a murine corneal wound model<br \/><\/em><br \/>\n          \n        <\/li>\n<li>\n          <em>U.S. FDA has recently approved a compassionate use request for topical B-VEC application to one eye in a RDEB patient<\/em><br \/>\n          \n        <\/li>\n<\/ul>\n<p>PITTSBURGH, Sept.  09, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UTBY3355ppy0kCn9haM9xq3aK7RCCqhpmoAuVYPF7wkcTdYOpxprPvOYDaT4oLKshFWqpfQBTJSLbLrw3yFidHpN1Rz-esTnf7vdpiOrze4=\" rel=\"nofollow noopener\" target=\"_blank\">Krystal Biotech Inc.<\/a>, (\u201cKrystal\u201d) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present data on its lead product candidate beremagene geperpavec (B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB) at the upcoming DEBRA International Conference 2021. Data to be presented includes preclinical evidence of safety and collagen VII expression after topical B-VEC application to induced corneal wounds. This preclinical study was conducted in response to a compassionate use request from a physician for the use of topical (eye drop) B-VEC in the eye of a single recessive DEB patient after undergoing surgical removal of the scared layer of the cornea. The U.S. FDA recently approved the physician\u2019s request.<\/p>\n<p>In the eye, persistent blistering due to mutations in the <em>COL7A1<\/em> gene can lead to a buildup of fibrotic scar tissue in the cornea, resulting in a loss of visual acuity and potentially leading to blindness. There are currently no approved treatments for DEB-associated corneal lesions.<\/p>\n<p>\n        <u>DEBRA International Presentation Details<\/u><br \/>\n        <br \/>\n        <strong>Oral Abstract Title: <\/strong>Topical Application of Beremagene Geperpavec, an Engineered Herpes Simplex Virus Type I-Based Gene Therapy Vector Expressing Type VII Collagen, is Safe and Efficacious in a Murine Corneal Wound Model <br \/><strong>Session date\/time:<\/strong> Thursday September 16, 18:10-18:20 (Moscow time)<br \/><strong>Session Title:<\/strong> Short Presentations<br \/><strong>Abstract Number: <\/strong>1<\/p>\n<p>\n        <strong>Oral Abstract Title:<\/strong> Technology Platform: Engineered HSV-1 Based Technology Enables Redosable Gene Delivery to Skin Cells Where One and Done Therapy is Not Applicable<br \/><strong>Session Date\/time:<\/strong> Friday September 17, 16:10-16:20 (Moscow time)<br \/><strong>Session Title:<\/strong> Clinical Trials 2<br \/><strong>Abstract Number:<\/strong> 5<\/p>\n<p>\n        <strong>e-Poster Title:<\/strong> Burden of Illness in Patients with Dystrophic Epidermolysis Bullosa in the US<br \/><strong>Poster Number:<\/strong> 18<\/p>\n<p>\n        <strong>e-Poster Title:<\/strong> Understanding the Socioeconomic Costs of Dystrophic Epidermolysis Bullosa in Europe<br \/><strong>Poster Number:<\/strong> 31<\/p>\n<p>The oral and poster presentations will be available to conference attendees. To register for the conference, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1t_1a1Lc02tJf9qdnYnY0bpLBVa1ZdaZfG5vSW4XPjS344Qt0TmK76ihYIXAn7MLhviCZCVulL43Sq_5-8wGnlQBHvRWPIjpoQfvcbh2kbw6_9zqafvq8zdBOXBboOG3\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/debracongress2021.ru\/register<\/a>.<\/p>\n<p>\n        <strong><br \/>\n          <em>About Krystal Biotech<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Krystal Biotech, Inc. (NASDAQ:KRYS) is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Z3H37U2AWotejEjw3M9T-N-QMMimjijvGRGxJCCJLCMxu3eBD0XadFa8KgOvmGFvio8Zo9ZCpwPY3Zo1OCt_J-LdiPJeWPCs5ZtCWWzMD6g=\" rel=\"nofollow noopener\" target=\"_blank\">http:\/\/www.krystalbio.com<\/a>.<\/p>\n<p>\n        <strong><br \/>\n          <em>Forward-Looking Statements<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Any statements in this press release about future expectations, plans and prospects for Krystal Biotech, Inc., including but not limited to statements about the development of Krystal\u2019s product candidates, such as plans for the design, conduct and timelines of ongoing pre-clinical and clinical trials of beremagene geperpavec (\u201cB-VEC\u201d), and Krystal\u2019s plans for filing of regulatory approvals and efforts to bring B-VEC to market; the market opportunity for and the potential market acceptance of B-VEC; plans to pursue research and development of other product candidates; the sufficiency of Krystal\u2019s existing cash resources; the unanticipated impact of COVID-19 on Krystal\u2019s business operations, pre-clinical activities and clinical trials; and other statements containing the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201cpotential,\u201d \u201clikely,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccontinue,\u201d and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or trials will be indicative of the results of ongoing or future trials, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercial potential of product candidates including B-VEC the sufficiency of cash resources and need for additional financing and such other important factors as are set forth under the caption \u201cRisk Factors\u201d in Krystal\u2019s annual and quarterly reports on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Krystal\u2019s views as of the date of this release. Krystal anticipates that subsequent events and developments will cause its views to change. However, while Krystal may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Krystal\u2019s views as of any date subsequent to the date of this release.<\/p>\n<p>\n        <strong>CONTACTS:<\/strong>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:50%;width:50%;min-width:50%\">\n            <strong>Investors:<\/strong>\u00a0<\/td>\n<td style=\"max-width:50%;width:50%;min-width:50%\">Media:<\/td>\n<\/tr>\n<tr>\n<td>Whitney Ijem<\/td>\n<td>Mary Coyle<\/td>\n<\/tr>\n<tr>\n<td>Krystal Biotech\u00a0<\/td>\n<td>TellMed Strategies<\/td>\n<\/tr>\n<tr>\n<td>wijem@krystalbio.com<\/td>\n<td>mary.coyle@tmstrat.com<\/td>\n<\/tr>\n<\/table>\n<p>Source: Krystal Biotech, Inc.<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjczMCM0Mzk2MzAwIzIwOTE5Nzk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MzZiYmYxYWUtMWZjZi00ODk2LWE4MzMtZjQ2YjYwYTc5NTI3LTExMDM1NTA=\/tiny\/Krystal-Biotech-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Data include evaluation of investigational B-VEC in a murine corneal wound model U.S. FDA has recently approved a compassionate use request for topical B-VEC application to one eye in a RDEB patient PITTSBURGH, Sept. 09, 2021 (GLOBE NEWSWIRE) &#8212; Krystal Biotech Inc., (\u201cKrystal\u201d) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present data on its lead product candidate beremagene geperpavec (B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB) at the upcoming DEBRA International Conference 2021. Data to be presented includes preclinical evidence of safety and collagen VII expression after topical B-VEC application to induced corneal wounds. This preclinical study was conducted in response to a compassionate use request from a physician &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-536230","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Data include evaluation of investigational B-VEC in a murine corneal wound model U.S. FDA has recently approved a compassionate use request for topical B-VEC application to one eye in a RDEB patient PITTSBURGH, Sept. 09, 2021 (GLOBE NEWSWIRE) &#8212; Krystal Biotech Inc., (\u201cKrystal\u201d) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present data on its lead product candidate beremagene geperpavec (B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB) at the upcoming DEBRA International Conference 2021. Data to be presented includes preclinical evidence of safety and collagen VII expression after topical B-VEC application to induced corneal wounds. This preclinical study was conducted in response to a compassionate use request from a physician &hellip; Continue reading &quot;Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-09T12:03:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjczMCM0Mzk2MzAwIzIwOTE5Nzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021\",\"datePublished\":\"2021-09-09T12:03:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\\\/\"},\"wordCount\":776,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMjczMCM0Mzk2MzAwIzIwOTE5Nzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\\\/\",\"name\":\"Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMjczMCM0Mzk2MzAwIzIwOTE5Nzk=\",\"datePublished\":\"2021-09-09T12:03:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMjczMCM0Mzk2MzAwIzIwOTE5Nzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMjczMCM0Mzk2MzAwIzIwOTE5Nzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\/","og_locale":"en_US","og_type":"article","og_title":"Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021 - Market Newsdesk","og_description":"Data include evaluation of investigational B-VEC in a murine corneal wound model U.S. FDA has recently approved a compassionate use request for topical B-VEC application to one eye in a RDEB patient PITTSBURGH, Sept. 09, 2021 (GLOBE NEWSWIRE) &#8212; Krystal Biotech Inc., (\u201cKrystal\u201d) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present data on its lead product candidate beremagene geperpavec (B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB) at the upcoming DEBRA International Conference 2021. Data to be presented includes preclinical evidence of safety and collagen VII expression after topical B-VEC application to induced corneal wounds. This preclinical study was conducted in response to a compassionate use request from a physician &hellip; Continue reading \"Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-09T12:03:51+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjczMCM0Mzk2MzAwIzIwOTE5Nzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021","datePublished":"2021-09-09T12:03:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\/"},"wordCount":776,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjczMCM0Mzk2MzAwIzIwOTE5Nzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\/","name":"Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjczMCM0Mzk2MzAwIzIwOTE5Nzk=","datePublished":"2021-09-09T12:03:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjczMCM0Mzk2MzAwIzIwOTE5Nzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjczMCM0Mzk2MzAwIzIwOTE5Nzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/krystal-biotech-to-present-data-on-deb-and-b-vec-at-the-debra-international-conference-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/536230","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=536230"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/536230\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=536230"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=536230"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=536230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}